{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:41:25Z","timestamp":1771630885028,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ajo.2018.04.012","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T08:29:57Z","timestamp":1524644997000},"page":"xv-xxii","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Retinal Neuroprotection: Overcoming the Translational Roadblocks"],"prefix":"10.1016","volume":"192","author":[{"given":"Thomas J.","family":"Wubben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cagri G.","family":"Besirli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Zacks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2018.04.012_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ajo.2009.03.029","article-title":"Neuroprotection: extrapolating from neurologic diseases to the eye","volume":"148","author":"Danesh-Meyer","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2018.04.012_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajo.2017.04.007","article-title":"Stem cells for retinal disease: a perspective on the promise and perils","volume":"179","author":"Rao","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2018.04.012_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pharmthera.2014.09.003","article-title":"Neuroprotection for ischaemic stroke: current status and challenges","volume":"146","author":"Moretti","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"Pt B","key":"10.1016\/j.ajo.2018.04.012_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.expneurol.2017.06.018","article-title":"Clinical approaches to the development of a neuroprotective therapy for PD","volume":"298","author":"Olanow","year":"2017","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.ajo.2018.04.012_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2012.08.005","article-title":"Solving the lost in translation problem: improving the effectiveness of translational research","volume":"13","author":"Ergorul","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ajo.2018.04.012_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2016.07.013","article-title":"Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants","volume":"170","author":"Birch","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2018.04.012_bib7","first-page":"3292","article-title":"Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa","volume":"43","author":"Tao","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2018.04.012_bib8","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1167\/iovs.03-0566","article-title":"Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures","volume":"45","author":"Hare","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ajo.2018.04.012_bib9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","article-title":"Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review","volume":"127","author":"Saylor","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.04.012_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/ICU.0b013e32834372ec","article-title":"Neuroprotection in glaucoma: recent and future directions","volume":"22","author":"Danesh-Meyer","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2018.04.012_bib11","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1167\/iovs.10-6304","article-title":"Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress","volume":"52","author":"Collier","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"28","key":"10.1016\/j.ajo.2018.04.012_bib12","doi-asserted-by":"crossref","first-page":"E279","DOI":"10.1073\/pnas.1100901108","article-title":"Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration","volume":"108","author":"Ding","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10097","key":"10.1016\/j.ajo.2018.04.012_bib13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2018.04.012_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1755-3768.2008.01459.x","article-title":"Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned","volume":"87","author":"Osborne","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.04.012_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/ICU.0b013e32834ff490","article-title":"Clinical trials for glaucoma neuroprotection are not impossible","volume":"23","author":"Quigley","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2018.04.012_bib16","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1167\/iovs.03-0567","article-title":"Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures","volume":"45","author":"Hare","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2018.04.012_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.exer.2016.12.005","article-title":"Lasker\/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. Neuroprotection for glaucoma: requirements for clinical translation","volume":"157","author":"Levin","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2018.04.012_bib18","first-page":"CD006539","article-title":"Neuroprotection for treatment of glaucoma in adults","volume":"1","author":"Sena","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.ajo.2018.04.012_bib19","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ajo.2018.04.012_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":"Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"395","key":"10.1016\/j.ajo.2018.04.012_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ajo.2018.04.012_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ng.3799","article-title":"Genome-wide analyses identify common variants associated with macular telangiectasia type 2","volume":"49","author":"Scerri","year":"2017","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ajo.2018.04.012_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajo.2014.04.003","article-title":"Visual field improvement in the collaborative initial glaucoma treatment study","volume":"158","author":"Musch","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2018.04.012_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ophtha.2003.09.025","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results","volume":"111","author":"Ederer","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2018.04.012_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/bjophthalmol-2012-302330","article-title":"Long-term visual acuity and the duration of macular detachment: findings from a prospective population-based study","volume":"97","author":"Mitry","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2018.04.012_bib29","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ajo.2018.04.012_bib30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.mam.2012.06.003","article-title":"Animal models of age related macular degeneration","volume":"33","author":"Pennesi","year":"2012","journal-title":"Mol Aspects Med"},{"issue":"2","key":"10.1016\/j.ajo.2018.04.012_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1242\/dmm.017913","article-title":"Biology and therapy of inherited retinal degenerative disease: insights from mouse models","volume":"8","author":"Veleri","year":"2015","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ajo.2018.04.012_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","article-title":"CRISPR\/Cas9 in genome editing and beyond","volume":"85","author":"Wang","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ajo.2018.04.012_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.preteyeres.2013.08.001","article-title":"Photoreceptor cell death and rescue in retinal detachment and degenerations","volume":"37","author":"Murakami","year":"2013","journal-title":"Prog Retin Eye Res"},{"issue":"10 Suppl","key":"10.1016\/j.ajo.2018.04.012_bib34","first-page":"S87","article-title":"Can molecular and cellular neuroprotection be translated into therapies for patients?: yes, but not the way we tried it before","volume":"41","author":"Tymianski","year":"2010","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ajo.2018.04.012_bib35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/jamaneurol.2013.6299","article-title":"Importance of preclinical research in the development of neuroprotective strategies for ischemic stroke","volume":"71","author":"Neuhaus","year":"2014","journal-title":"JAMA Neurol"},{"issue":"299","key":"10.1016\/j.ajo.2018.04.012_bib36","doi-asserted-by":"crossref","first-page":"299fs32","DOI":"10.1126\/scitranslmed.aac9412","article-title":"Neuroprotective therapies: preclinical reproducibility is only part of the problem","volume":"7","author":"Tymianski","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ajo.2018.04.012_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/bjophthalmol-2014-305550","article-title":"Biomarkers and surrogate endpoints in glaucoma clinical trials","volume":"99","author":"Medeiros","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2018.04.012_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.10.001","article-title":"Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma","volume":"56","author":"De Moraes","year":"2017","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.ajo.2018.04.012_bib39","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ophtha.2016.01.034","article-title":"Anatomic clinical trial endpoints for nonexudative age-related macular degeneration","volume":"123","author":"Schaal","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2018.04.012_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molmed.2017.11.004","article-title":"Monitoring neurodegeneration in glaucoma: therapeutic implications","volume":"24","author":"Ban","year":"2018","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.ajo.2018.04.012_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/08820538.2011.577132","article-title":"Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures","volume":"26","author":"Yehoshua","year":"2011","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2018.04.012_bib42","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/IAE.0000000000001002","article-title":"Visual function measures in early and intermediate age-related macular degeneration","volume":"36","author":"Chandramohan","year":"2016","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2018.04.012_bib43","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2014.02.005","article-title":"Low-luminance visual acuity and microperimetry in age-related macular degeneration","volume":"121","author":"Wu","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2018.04.012_bib44","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ddstr.2012.11.002","article-title":"Visual function endpoints to enable dry AMD clinical trials","volume":"10","author":"Lesmes","year":"2013","journal-title":"Drug Discov Today Ther Strateg"},{"issue":"1","key":"10.1016\/j.ajo.2018.04.012_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.survophthal.2017.05.003","article-title":"Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration","volume":"63","author":"Kersten","year":"2018","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2018.04.012_bib46","doi-asserted-by":"crossref","first-page":"BIO27","DOI":"10.1167\/iovs.17-21778","article-title":"Biomarkers and surrogate endpoints in drug development: a European regulatory view","volume":"58","author":"Wickstr\u00f6m","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2018.04.012_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-vision-102016-061422","article-title":"Neuroprotection in glaucoma: animal models and clinical trials","volume":"3","author":"Almasieh","year":"2017","journal-title":"Annu Rev Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2018.04.012_bib48","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.ophtha.2017.06.032","article-title":"Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration","volume":"124","author":"Sleiman","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2018.04.012_bib49","doi-asserted-by":"crossref","first-page":"BIO255","DOI":"10.1167\/iovs.17-21868","article-title":"Photoreceptor-based biomarkers in AOSLO retinal imaging","volume":"58","author":"Litts","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.ajo.2018.04.012_bib50","doi-asserted-by":"crossref","first-page":"BIO88","DOI":"10.1167\/iovs.17-21809","article-title":"Omics biomarkers in ophthalmology","volume":"58","author":"Lauwen","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.ajo.2018.04.012_bib51","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2018.04.012_bib52","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"issue":"6326","key":"10.1016\/j.ajo.2018.04.012_bib54","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ajo.2018.04.012_bib55","doi-asserted-by":"crossref","DOI":"10.1007\/s10571-017-0572-3","article-title":"Up-regulated pro-inflammatory microRNAs (miRNAs) in Alzheimer's disease (AD) and age-related macular degeneration (AMD)","author":"Pogue","year":"2018","journal-title":"Cell Mol Neurobiol"},{"issue":"16","key":"10.1016\/j.ajo.2018.04.012_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93621","article-title":"Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease","volume":"2","author":"Koronyo","year":"2017","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.ajo.2018.04.012_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective effects of angiotensin receptor blockers","volume":"28","author":"Villapol","year":"2015","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.ajo.2018.04.012_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12906-017-1922-x","article-title":"Neuroprotective properties of curcumin in toxin-base animal models of Parkinson's disease: a systematic experiment literatures review","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Complement Altern Med"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418301818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418301818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:38:41Z","timestamp":1757597921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939418301818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":54,"alternative-id":["S0002939418301818"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2018.04.012","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinal Neuroprotection: Overcoming the Translational Roadblocks","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2018.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}